With the European Medicines Agency (EMA) approval of a third generation TKI for advanced NSCLC patients, the request for EGFR T790M resistance mutation detection for stratification of lung cancer patients eligible for treatment increased significantly. This evidence concerns the gene EGFR and lung cancer.